Daniel Pella
Impact in
-
- Antiplatelet Therapy and Cardiovascular Diseases
- Surgery top 0.05%
- Lipoproteins and Cardiovascular Health
Papers in
-
- Blood Pressure and Hypertension Studies 9
- Surgery 39
- Lipoproteins and Cardiovascular Health 32
- Co-authors
- Ram Bahadur Singh (42 shared papers)Mohammad A. Niaz (4 shared papers)Elliot M. Berry (2 shared papers)Orly Manor (2 shared papers)Saraswati Ghosh (2 shared papers)Gal Dubnov‐Raz (1 shared paper)Shanti S. Rastogi (2 shared papers)Reema Singh (1 shared paper)
- Journals
- Archives of Medical Science (9 papers)International Journal of Environmental Research and Public Health (8 papers)The Lancet (7 papers)European Heart Journal (6 papers)Pharmacological Research (5 papers)
- Partner nations
- SlovakiaIndiaUnited States
In The Last Decade
Daniel Pella
156 papers receiving 26.4k citations
Daniel Pella's Hit Papers
Peers
Comparison fields: 5 of 166
- Cardiology and Cardiovascular Medicine 5.6k
- Surgery 9.6k
- Endocrinology, Diabetes and Metabolism 3.4k
- Immunology 3.5k
- Internal Medicine 392
Countries citing papers authored by Daniel Pella
This map shows the geographic impact of Daniel Pella's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Pella with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Pella more than expected).
Fields of papers citing papers by Daniel Pella
This network shows the impact of papers produced by Daniel Pella. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Pella. The network helps show where Daniel Pella may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel Pella, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 164 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease Hit paper breakdown → | 2017 | 7350 |
| 2 | 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk Hit paper breakdown → | 2019 | 6610 |
| 3 | 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk Hit paper breakdown → | 2019 | 4219 |
| 4 | Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2017 | 1106 |
| 5 | Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial Hit paper breakdown → | 2017 | 743 |
| 6 | Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2017 | 671 |
| 7 | Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2017 | 607 |
| 8 | 2002 | 539 | |
| 9 | 2014 | 378 | |
| 10 | Prevalence of statin intolerance: a meta-analysis Hit paper breakdown → | 2022 | 327 |
| 11 | 2015 | 323 | |
| 12 | 2017 | 255 | |
| 13 | 2017 | 243 | |
| 14 | Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial Hit paper breakdown → | 2019 | 239 |
| 15 | 2018 | 234 | |
| 16 | 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias Hit paper breakdown → | 2025 | 204 |
| 17 | 2019 | 159 | |
| 18 | 2015 | 138 | |
| 19 | 2019 | 116 | |
| 20 | 2021 | 114 |
About Daniel Pella
Daniel Pella is a scholar working on Cardiology and Cardiovascular Medicine, Surgery, Endocrinology, Diabetes and Metabolism, Nutrition and Dietetics and Public Health, Environmental and Occupational Health, having authored 164 papers that have together received 27.3k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (32 papers), Nutritional Studies and Diet (16 papers), Romani and Gypsy Studies (16 papers), Diet and metabolism studies (12 papers), Coenzyme Q10 studies and effects (11 papers), Fatty Acid Research and Health (10 papers), Blood Pressure and Hypertension Studies (9 papers) and Health Systems, Economic Evaluations, Quality of Life (9 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (5.6k citations), Surgery (9.6k citations), Endocrinology, Diabetes and Metabolism (3.4k citations), Immunology (3.5k citations) and Internal Medicine (392 citations). Daniel Pella has collaborated with scholars based in Slovakia, India and United States. Frequent co-authors include Ram Bahadur Singh, Mohammad A. Niaz, Elliot M. Berry, Orly Manor, Saraswati Ghosh, Gal Dubnov‐Raz, Shanti S. Rastogi, Reema Singh, Péter Jarcuska and Ján Fedačko. Their work appears in journals such as Archives of Medical Science, International Journal of Environmental Research and Public Health, The Lancet, European Heart Journal and Pharmacological Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.